19th Annual Clinical Trial Supply Europe 2018
This year’s Clinical Trial Supply event builds on last year’s incredibly successful conference, and is to date our biggest conference yet. We have representatives from 6 of the top 10 pharmaceutical companies in Europe, who will be joined by leading biotech companies across the continent to jointly find solutions for your clinical trial supply problems and discuss changes in the industry.
As a streamed event this conference promises to address a larger variety of topics, with sessions covering all the essentials in clinical supply, from maximising forecasting software to patient centric strategies for supply chain and considering methods to achieve last mile delivery.
CTS Europe will take place in Milan on the 14th and 15th of March, 2018 and we are extremely excited to see you there!
What new sessions will the 2018 programme include?
This year’s conference promises to be our most exciting to date, with presentations from some of the industry’s top leading experts in the field of clinical trial supply. The following are a sample of what you will find in Milan in March:
After two successful years in Barcelona, CTS Europe is moving to the beautiful city of Milan, Italy’s manufacturing heartland. Since the late 1800s, Milan has been an important industrial and manufacturing centre, especially for the automotive industry, chemicals, machinery, pharmaceuticals and plastics, health and biotechnology and food beverage.
What to expect
The 2018 programme will host speakers from the likes of Sanofi, Teva, Merck, AstraZeneca, Janssen and GlaxoSmithKlein as well as a number of small to mid-sized biotechs like Spektrum Cannabis, 4SC AG or Shield Pharma. Through this two day conference, we will discoverthe practical benefits of e-labeling, while examining tech-driven ways to overcome issues and maximize current technologies to get the best result for your clinical supplies. There will also be stimulating roundtable discussions .
Moving forward, the Direct-to-Patient approach
It is commonly known that clinical trials are complex to operate, demanding protocols and patient recruitment are just some of the issues which many sponsors face today. With multiple complications, new initiatives are always being tested to minimize these discouraging features. One new initiative, the Direct-to-Patient method, has risen in the past decade.
The impact of EU 536/2014
Currently, conducting clinical trials within the European Union (EU) can be problematic, making the continent a less favorable location in comparison to other regions. To combat such issue, the EU has introduced a new regulation which replaces the European Clinical Trials Directive (2001/20/EC). The aim of EU 536/2014 is to create a more favorable environment for clinical trials, and to harmonise the requirements for performing clinical trials within the EU member states.
What did our 2017 audience have to say?
“Very well organized and in a excellent and charm environment. Most of the people were really interested in the presentations as well as participating in the interactive exercise. A really positive experience.” – Merck